Research
Print page Print page
Switch language
The Capital Region of Denmark - a part of Copenhagen University Hospital
Published

Successful treatment with Ipilimumab and Interleukin-2 in two patients with metastatic melanoma and systemic autoimmune disease

Research output: Contribution to journalJournal articleResearchpeer-review

  1. Evidence of immune elimination, immuno-editing and immune escape in patients with hematological cancer

    Research output: Contribution to journalReviewResearchpeer-review

  2. Arginase-1-based vaccination against the tumor microenvironment: the identification of an optimal T-cell epitope

    Research output: Contribution to journalReviewResearchpeer-review

  3. TAM-ing T cells in the tumor microenvironment: implications for TAM receptor targeting

    Research output: Contribution to journalReviewResearchpeer-review

  4. Tumor-induced escape mechanisms and their association with resistance to checkpoint inhibitor therapy

    Research output: Contribution to journalReviewResearchpeer-review

  5. Cancer immunotherapy in patients with brain metastases

    Research output: Contribution to journalReviewResearchpeer-review

  1. Genome-wide CRISPR-Cas9 screening reveals ubiquitous T cell cancer targeting via the monomorphic MHC class I-related protein MR1

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Peripheral Nervous System Disease in Systemic Lupus Erythematosus: Results From an International Inception Cohort Study

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Tertiary lymphoid structures improve immunotherapy and survival in melanoma

    Research output: Contribution to journalJournal articleResearchpeer-review

  4. Reliable cell and tissue morphology-based diagnosis of endemic Burkitt lymphoma in resource-constrained settings in Ghana

    Research output: Contribution to journalJournal articleResearchpeer-review

View graph of relations

Two patients were treated with immunotherapy for metastatic malignant melanoma (MM) despite suffering from systemic autoimmune disease, i.e., ulcerative colitis (UC) and Behcets disease (BD), respectively. Both patients benefitted from the treatment. The patient with UC achieved partial remission of all measurable parameters after treatment with Ipilimumab, while the patient with BD achieved a complete remission of MM after treatment with Interleukin-2 (IL-2) and Interferon-α (IFN-α). Moreover, no aggravation of symptoms related to the autoimmune diseases was seen during treatment, in contrast, clinical indications of improvement were observed. These two cases illustrate that the presence of autoimmune disease does not necessarily predict increased autoimmune toxicity in connection with immunotherapy. They also raise the question of whether autoimmune disease should continue to be an absolute exclusion criterion for treatment of MM with immunotherapy. Consequently, given the poor prognosis of refractory MM, immunotherapies need to be taken into consideration even in cases of autoimmune comorbidity due to the potential long-term benefit that these therapies offer to MM patients.

Original languageEnglish
JournalCancer immunology, immunotherapy : CII
Volume63
Issue number12
Pages (from-to)1341-6
Number of pages6
ISSN0340-7004
DOIs
Publication statusPublished - Dec 2014

ID: 44852847